Member Info for Candid

It’s been long time getting here and first drilling is imminent. Looks like a very busy Q4 with planned spud of 5 targets.
Starting to imagine a decent gas discovery at Egyptian Vulture followed by an oil discovery at Rodhette

KAP was hugely oversold in recent weeks with heavy selling by the GlobalX Uranium ETF (forced weighting rebalancing). This looks to be on the rebound now and catching up to the positive developments in uranium such as the Sprott Physical Uranium Trust mopping up volumes of U308 from spot market, rising demand for spot purchases from various sources including Cameco and KAP. All this means utilities will have to enter contracting sooner rather than later or risk potential supply problems and then this will really come alive. In the meantime ongoing purchases by SPUT will keep the pressure on.

Good news today, this US grant is just a taste of things to come. The US pharma industry is predatory and when it recognises potential breakthrough products or technology it usually ends up owning it. I can see a takeover within 12 months here.

good article, if the exit by Shell from the Norwegian Continental Shelf does materialise, expect LBE to be in the running for any M&A deals. Size depending of course.
“Rystad expects more transactions potentially to come in the light of Shell’s public statements of plans for an exit from the NCS. Shell currently has a strong position on the NCS”

Really tempted to get in here, I think HOC is good value if your outlook on gold and silver is bullish. The rare earths project looks interesting too.
Most gold miners have sold off this summer and HOC a bit more than most, possibly due to the Peru country risk following the leftist election win.
I might wait till the Peru tax reform is more clear as this will inevitably lead to an increase in mining taxes/royalties. Unfortunately HOC’s tax stability agreement expired in 2018 so they are not protected from any mining tax rises.

As per the last RNS the POC product is completing final tests necessary before CE marking (end Sept/early Oct) and a commercial launch in the EU.
In anticipation of this the company is engaging with commercial partners, so I’m guessing the next announcement may be partnership news.

This positive secondary endpoint data will make phase 3 trial design all the more robust, regulators will like the primary and secondary data. It will also put DEST in an even better position when negotiating with a big pharma or biotech fund partner for the phase 3 trial

Launch of the next significant product, the Universal Immuno-Oncology (IO) Response Test, is due by the end of the current financial year, I make that by the end of September 2021, so we could see news on this soon.

talking to myself here but on some additional reading I have seen that the CST sales were delayed till June due to lab equipment issues that are resolved now, this times well with the current covid wave and sales should be growing

The severity test launched in the US in March 2021 and I believe this test was the first of it’s kind anywhere in the world. I’m very keen to learn about how many have been ordered as OBD had an early mover advantage on this test. I’m a bit puzzled why it was not also launched in the UK or Europe?
Recently another severity test was launched in the UK by MeMed of Israel and this has received CE mark for sale in UK.
I can understand the focus on US as it’s a large market where this type of test would be in demand, but keen to know actual sale volumes.
https://covidseveritytest.com

This is all about launching and building a successful brand and by the looks of it they have one of the best teams to do this with a proven track record and experience. Collaboration with the founder of the REN brand of skincare is particularly noteworthy.

I’m a fan of what SNG are developing and am confident of a positive read-out of the pivotal Phase 3 hospital trial.
As regarding the Home cohort element of treatment I’m not so sure. Following the UK home trial results the company have concluded that some benefits were seen only in patients who are markedly/severely breathless and that any future treatment should be targeted on patients who have had a breathless assessment. In the real world I just can’t see how this will work in a home setting as any patients that have developed breathlessness will not hang around at home and are currently advised to contact emergency services for hospital admission. I just can’t see any patients taking the risk of staying at home without the support of a hospital environment for treatment at this stage.
In my opinion the Active-2 trial will likely produce similar results to SNG’s own Home cohort trial and this could pose a risk for Active-2 not progressing to a phase-3 element. I could be wrong as some targeted patients could be sought but in my opinion this will be difficult to carry out.
Treatment in the hospital environment looks the most likely path and I am confident this will have a positive outcome.

Further great news today regarding XF-73. After the drift in share price this is looking very undervalued considering the positive data coming out and the further de-risking.
DEST are in a great position now to attract significant partnerships for both XF-73 and M3 and I’m looking forward to more news on both of these flagship projects

After this week’s bounce in uranium equities, I think we’ll see further upward revisions of the NAV here, the July selloff has provided a good entry point here.

Appreciate the views guys, it seems Bronte hold open positions in various international markets and I agree it looks like a punt. The thing that made me feel a bit uneasy is that Bronte is an Australian hedge fund and the drilling contractor for Rukwa (Mitchells) is also an Aussie company.

B1ll, you can click on the ‘HE1 short positions’ icon on this site or visit the shorttracker website

A new short position was opened a couple days ago, only 0.5%, but it makes you wonder why they opened this position? Don’t know if I missed it but has this been discussed on here yet?

News today of the subsea cable project is probably one of many. This is a good longterm hold, with slow but steady growth.
I’ve noticed the short position has been closed out a few weeks ago by Millennium, so that was a short lived short

That’s a good observation Bright1232, and something I have picked up on too. However I don’t think Activ-2 have changed their trial protocol to focus on patients with breathless symptoms only as they started recruiting for the trial in Feb, while the results of the UK HOME cohort was reported in April, so conclusions from that may not have influenced the trial protocol of ACTIV-2 to change (don’t even know if this is allowed). Perhaps a more realistic view is that if SNG001 gets moved to phase 3 in Active-2, the new trial protocol might specify recruitment of cases with breathlessness only? Perhaps. That would definitely make sense.
I also think Synairgen may be in talks to participate in existing/planned trials to target exactly these type of home cases (breathlessness).

According to a Spanish press article.
‘The CSN will rule on Friday on the Retortillo uranium mine after the denunciation of threats’
Hence the rise yesterday. Not sure at what time this ruling will come but it is significant. I’m out for now as a negative ruling would probably kill this project, not saying a positive outcome is not possible but the risk is too big.
DYOR